Patents by Inventor Alex Sparreboom

Alex Sparreboom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SLCO1B3 genotype
    Patent number: 10094836
    Abstract: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: October 9, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: William D. Figg, Alex Sparreboom, Akinobu Hamada, Douglas K. Price, Tristan M. Sissung
  • ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity
    Patent number: 8835115
    Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: September 16, 2014
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Universitätsklinikum Freiburg
    Inventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
  • SLCO1B3 GENOTYPE
    Publication number: 20100317726
    Abstract: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
    Type: Application
    Filed: January 8, 2008
    Publication date: December 16, 2010
    Applicant: Government of the United States of America, as rep resented by the Secretary Dept. of Health and Hum
    Inventors: William D. Figg, Alex Sparreboom, Akinobu Hamada, Douglas K. Price, Tristan M. Sissung
  • Cyp1B1 Genotype
    Publication number: 20100280084
    Abstract: The invention relates to pharmacology, pharmacokinetics and toxicology, and more specifically to methods of identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It further related to the genetic basis of inter-patient variation in response to therapy, including drug therapy, and to methods for determining and exploiting such differences to improve medical outcomes.
    Type: Application
    Filed: September 8, 2006
    Publication date: November 4, 2010
    Applicant: Government of the US, as represented by the Secret ary, Department of Health and Human Services
    Inventors: William D. Figg, Alex Sparreboom, Tristan M. Sissung, Douglas K. Price
  • ABCB1 GENOTYPING TO PREDICT MICROTUBULE-STABILIZING-AGENT-INDUCED TOXICITY
    Publication number: 20100247481
    Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.
    Type: Application
    Filed: July 13, 2007
    Publication date: September 30, 2010
    Inventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke